Kwality Pharma expands global reach with successful EU-GMP audit

Kwality Pharmaceuticals Limited has successfully completed a European Union Good Manufacturing Practices (EU-GMP) audit at its Amritsar manufacturing facilities, encompassing both the general and beta-lactam units. The audit concluded with no major observations, underscoring the company's commitment to high international quality and compliance standards.

This achievement marks a significant milestone, reinforcing Kwality Pharma's dedication to manufacturing excellence and regulatory adherence. With this successful audit, the company now boasts four EU-approved facilities, including general, beta-lactam, cephalosporin, and oncology. This strengthens its position as a trusted global pharmaceutical manufacturer across various therapeutic areas and dosage forms.

The successful EU-GMP audit highlights Kwality Pharma's commitment to patient safety, quality assurance, and global compliance, enabling the company to expand its presence across regulated international markets. This expansion is expected to unlock new opportunities for sustainable growth and strategic collaborations. The announcement was made on November 6, 2025.